Lessee, Operating Lease, Liability, to be Paid, Year Four of Acrivon Therapeutics, Inc. from 30 Sep 2022 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
Acrivon Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid, Year Four in USD history and change rate from 30 Sep 2022 to 31 Dec 2024.
  • Acrivon Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Four for the quarter ending 31 Dec 2024 was $404,000, a 66% decline year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year Four, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year Four, YoY Quarterly Change (%)

Acrivon Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Four (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $404,000 -$796,000 -66% 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $404,000 -$796,000 -66% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $404,000 -$796,000 -66% 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 $404,000 -$796,000 -66% 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $1,200,000 +$35,000 +3% 31 Dec 2023 10-K 28 Mar 2024 2023 FY
Q3 2023 $1,200,000 +$35,000 +3% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $1,200,000 30 Jun 2023 10-Q 11 Aug 2023 2023 Q2
Q1 2023 $1,200,000 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $1,165,000 31 Dec 2022 10-K 28 Mar 2023 2022 FY
Q3 2022 $1,165,000 30 Sep 2022 10-Q 15 Dec 2022 2022 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.